Questions about COVID-19? Has COVID-19 made paying for your medicine a challenge? AbbVie may be able to help.
Call 1.800.4HUMIRA or tapclick to learn more ▸

What Is HUMIRA?

Child with curly hair smiling to the camera

Learn if HUMIRA may be right for your child’s pediatric ulcerative colitis

HUMIRA is a prescription medication approved to treat moderate to severe pediatric ulcerative colitis (UC) in children as young as 5 years of age. HUMIRA can be administered by you, or your child, at home using the auto-injector Pen or pre-filled syringe. Be sure to get trained by a health care professional on how to prepare and administer HUMIRA before doing it yourself. Your child’s first injection must be given under the supervision of a health care professional.

HUMIRA can reduce the damaging inflammation of the digestive tract that is associated with moderate to severe pediatric ulcerative colitis. One factor involved in pediatric ulcerative colitis is the overproduction of an inflammation-causing protein called "tumor necrosis factor alpha" (TNF Alpha) that occurs naturally in the body.

HUMIRA specifically binds to TNF alpha and blocks its interaction with other cells. This helps reduce the systemic inflammation that can lead to pediatric UC, and can help your child achieve and maintain remission—few or no symptoms. With their symptoms under control, your child may be able to return to the activities that they enjoyed previously.

HUMIRA can be administered to your child using the HUMIRA Pen.

HUMIRA is also available as a prefilled syringe.

If you use the HUMIRA Pen, you can expect:

That you, or your child, can administer treatment in your own home after proper training by a health care professional
A thinner needle* compared to the original HUMIRA presentation
Not to see the needle before and during the administration process

Learn about HUMIRA with the
thinner needle

*Compared to HUMIRA 40 mg/0.8 mL.


	Over 1.4 million people worldwide are currently being treated with HUMIRA for different conditions.


	HUMIRA has been studied for more than 17 years to treat inflammatory bowel disease and is now approved to treat moderate to severe pediatric ulcerative colitis (UC).

With HUMIRA, remission is possible for your child

The goal of pediatric ulcerative colitis treatment is remission—few or no symptoms.

In a clinical study, a majority of patients were in remission after just 8 weeks.

Many pediatric patients have achieved long-term remission

Many patients who responded by week 8 were in remission at 1 year.

Many of these patients maintained clinical remission at 1 year.

Additionally, a majority of those who responded by week 8 continued to achieve symptom relief at 1 year.

Dosing and Administration

US-HUMG-200274